Recent Updates
Recently added Catalysts
ABBV

AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director AbbVie issued the following forms today. IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER ...

Key Takeaway: NORTH CHICAGO, Ill. , June 27, 2019 /PRNewswire/ -- AbbVie issued the following forms today. Related Links http://www.abbvie.com 21 %

Full Press Release Details

NORTH CHICAGO, Ill. , June 27, 2019 /PRNewswire/ -- AbbVie issued the following forms today.
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
Name of person dealing (Note 1) Roxanne S. Austin
Company dealt in AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2) Common shares, par value $0.01 per share
Date of dealing 26 June 2019
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
(1) Relevant securities 52,114 Common Shares (0.004%)
(2) Derivatives (other than options) N/A
(3) Options and agreements to purchase/sell N/A
Total 52,114 Common Shares (0.004%)
Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
Purchase 11500 common shares $67.50
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) YES/NO √
Date of disclosure 27 June 2019
Contact name Steven L. Scrogham
Telephone number 847-938-6166
Name of offeree/offeror with which acting in concert AbbVie Inc.
Specify category and nature of acting in concert status Director of AbbVie Inc.
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
Name of person dealing (Note 1) William J. Chase
Company dealt in AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2) Common shares, par value $0.01 per share
Date of dealing 26 June 2019
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
(1) Relevant securities 169,552 Common Shares (0.01%)
(2) Derivatives (other than options) N/A
(3) Options and agreements to purchase/sell 641,027 Options (0.04%) 112,376 Performance Shares (0.01%) under AbbVie Share Plans
Total 922,955 (0.06%)
Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
Purchase 30400 common shares $67.30
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) YES/NO√
Date of disclosure 26 June 2019
Contact name Steven L. Scrogham
Telephone number 847-938-6166
Name of offeree/offeror with which acting in concert AbbVie Inc.
Specify category and nature of acting in concert status Director of subsidiaries of AbbVie Inc.
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
Name of person dealing (Note 1) Edward J. Rapp
Company dealt in AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2) Common shares, par value $0.01 per share
Date of dealing 26 June 2019
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
(1) Relevant securities 30,662 Common Shares (0.002%)
(2) Derivatives (other than options) 14,907 stock equivalent units (0.001%)
(3) Options and agreements to purchase/sell N/A
Total 45,569 (0.003%)
Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
Purchase 7500 common shares $67.30
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) YES/NO√
Date of disclosure 27 June 2019
Contact name Steven L. Scrogham
Telephone number 847-938-6166
Name of offeree/offeror with which acting in concert AbbVie Inc.
Specify category and nature of acting in concert status Director of AbbVie Inc.

Related Links

21 %

Last updated: Jun 27, 2019